Attached files
| file | filename |
|---|---|
| EX-99.1 - AMENDED AND RESTATED BYLAWS - CYTOGENIX INC | cyto8kex991111810.htm |
United States
Securities and Exchange Commission
Washington, D.C. 20549
_______________________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 18, 2010
CytoGenix, Inc.
(Exact name of registrant as specified in its charter)
0-26807
(Commission File Number)
|
Nevada
|
76-048409
|
|
(State or other jurisdiction of incorporation)
|
(IRS Employer Identification No.)
|
|
710 N. Post Oak Road, Suite 410, Houston, TX
|
77024
|
|
(Address of principal executive offices)
|
(Zip Code)
|
(713) 780-0806
Registrant’s telephone number, including area code
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.03. AMENDMENTS TO ARTICLES OF INCORPORATION OR BYLAWS; CHANGE IN FISCAL YEAR.
On November 18, 2010, the Board of Directors of CytoGenix, Inc ("CYGX.PK") (the “Company”) amended the bylaws of the Company.
Exhibits.
|
99.1
|
Amended and Restated Bylaws of CytoGenix, Inc.
|
|
SIGNATURES
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: November 18, 2010
|
CytoGenix, Inc.
|
|
By /s/ Cy Stein
Cy Stein, Chief Executive Officer
|
2